Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
eNq9WN9v2jAQfueviPKwtyQESqFboNpYuyG1GqNFm/aCTHKAmWOn/kGhf/0cQlc6JepqcF8ixXa+O9+dv/vi6HydEmcFXGBGu27o110HaMwSTOddd3x76XXc814tWqIV2lvW9ut+2HCdmCAhum4+608BUeH/vL76DPp74G6v5kRsuoRYPlunJCb+VyQW1yjL1zjRiuHESUEuWNJ1MyW3o04kJNde9O4Z/y0yFEMU7Eb2Z5eTk/3xKMjB/gNVCeBXiM5LQYEaYcaKc6CyjyTMGd9U+Ns0wsZiBIIpHsMQycWQsxVOICk1MUNEgJGR2X1yA3xFQOZGSsGDZZwKI3C0ROsR3A3Knf6oZ/tyLb26F7bbZ51m6/Q07DTrRqb4XqjKs6A3EcSTsF0PG51mADTY6H2zjZcCQZSl4DVAPwieU/BwhglOVYqmhpkbMi4RsZQzLPrPy86SHQ53L9ZGgkVG0MZfisw0VIgjPQ1ck4O9jeQ7uOWaroiO2T/4VBESvNLr8Y5MLHmcc1WfKSorOOVyZBqIPqMS1tUZNaNBud7VIgZxPNgHRstbwFBNCY5NCU9TkgIhx6NBNd+9HVV8QgLG3B5X/MA0Yffi+By0n3NL3mdbGi0FzXgSThpnndOw1TI+Yr90gVV0pwvFWQaBZicsDiGdAZ2xQ+lG12w51GPFvlGxbhUUixGBCg3lGfKSrtJHyWftHNg7Y8VEKeiXi1vT4vmugG9utq+l0Djp/k27GWnb6AS6VF9yvDjU3WzSrLc6Z82TdyjNPjyK866hEC9ArehwxcsZaCFlJt4HAcqwv0DCE0jH059x0/5xXhqYYwRHk/VTru39SFiRFoXUKojakuvTogO/Lsmmx/ol8XGooN59vxPupTYkV3BALooOYI2nBxfHp/4nNW3N7eEzArJnZqt8kcSM2tJcalqKeFiz0Xmll1wTxLfZDFdc7FTWZRQUl0q9WhTkF0q92h9BpS14
zRvmNqy9c4CvsaL2
